Bruce J Kinon
Overview
Explore the profile of Bruce J Kinon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
2165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kinon B, Leucht S, Tamminga C, Breier A, Marcus R, Paul S
J Clin Psychiatry
. 2024 Aug;
85(3).
PMID: 39196873
Schizophrenia is a complex syndrome with taxing symptoms and for which treatment challenges remain. Current dopamine Dreceptor-blocking antipsychotics have well-known limitations, including ineffectively treating across all symptom domains and generating...
2.
Bailey S, Bast T, Chaby L, Kinon B, Harte M, Mead S, et al.
J Psychopharmacol
. 2023 Jul;
37(11):1051-1057.
PMID: 37522187
Animal models are important in preclinical psychopharmacology to study mechanisms and potential treatments for psychiatric disorders. A working group of 14 volunteers, comprising an international team of researchers from academia...
3.
Fonseca de Freitas D, Agbedjro D, Kadra-Scalzo G, Francis E, Ridler I, Pritchard M, et al.
J Psychopharmacol
. 2022 Oct;
36(11):1226-1233.
PMID: 36268751
Background: There is evidence of heterogeneity within treatment-resistant schizophrenia (TRS), with some people not responding to antipsychotic treatment from illness onset and others becoming treatment-resistant after an initial response period....
4.
A predictor model of treatment resistance in schizophrenia using data from electronic health records
Kadra-Scalzo G, Fonseca de Freitas D, Agbedjro D, Francis E, Ridler I, Pritchard M, et al.
PLoS One
. 2022 Sep;
17(9):e0274864.
PMID: 36121864
Objectives: To develop a prognostic tool of treatment resistant schizophrenia (TRS) in a large and diverse clinical cohort, with comprehensive coverage of patients using mental health services in four London...
5.
Kane J, Kinon B, Forray C, Such P, Mittoux A, Lemming O, et al.
Schizophr Res
. 2022 Sep;
248:271-278.
PMID: 36115192
Introduction: Treatment resistance constitutes the highest burden of disease within schizophrenia. We hypothesized that the synergistic activity of Lu AF35700 at dopamine D and D receptors might provide superior antipsychotic...
6.
Fonseca de Freitas D, Kadra-Scalzo G, Agbedjro D, Francis E, Ridler I, Pritchard M, et al.
J Psychopharmacol
. 2022 Feb;
36(4):498-506.
PMID: 35212240
Background: A proportion of people with treatment-resistant schizophrenia fail to show improvement on clozapine treatment. Knowledge of the sociodemographic and clinical factors predicting clozapine response may be useful in developing...
7.
Raket L, Jaskolowski J, Kinon B, Brasen J, Jonsson L, Wehnert A, et al.
Lancet Digit Health
. 2020 Dec;
2(5):e229-e239.
PMID: 33328055
Background: Many individuals who will experience a first episode of psychosis (FEP) are not detected before occurrence, limiting the effect of preventive interventions. The combination of machine-learning methods and electronic...
8.
Oliver D, Wong C, Bog M, Jonsson L, Kinon B, Wehnert A, et al.
Transl Psychiatry
. 2020 Oct;
10(1):364.
PMID: 33122625
The real-world impact of psychosis prevention is reliant on effective strategies for identifying individuals at risk. A transdiagnostic, individualized, clinically-based risk calculator to improve this has been developed and externally...
9.
Ambrosen K, Skjerbaek M, Foldager J, Axelsen M, Bak N, Arvastson L, et al.
Transl Psychiatry
. 2020 Aug;
10(1):276.
PMID: 32778656
The reproducibility of machine-learning analyses in computational psychiatry is a growing concern. In a multimodal neuropsychiatric dataset of antipsychotic-naïve, first-episode schizophrenia patients, we discuss a workflow aimed at reducing bias...
10.
Consistency checks to improve measurement with the Montgomery-Asberg Depression Rating Scale (MADRS)
Rabinowitz J, Schooler N, Brown B, Dalsgaard M, Engelhardt N, Friedberger G, et al.
J Affect Disord
. 2019 Jun;
256:143-147.
PMID: 31176186
International Society for CNS Clinical Trials and Methodology convened an expert Working Group that assembled consistency/inconsistency flags for the Montgomery-Asberg Depression Rating Scale (MADRS). Twenty-two flags were identified. Seven flags...